Literature DB >> 3207605

Peritoneal trauma releases CA125?

C W Redman1, S R Jones, D M Luesley, S E Nicholl, K Kelly, E J Buxton, K K Chan, G R Blackledge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3207605      PMCID： PMC2246796          DOI： 10.1038/bjc.1988.250

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  CA 125 in gynecologic practice.

Authors:  G D Malkasian; K C Podratz; C R Stanhope; R E Ritts; V R Zurawski
Journal:  Am J Obstet Gynecol       Date:  1986-09       Impact factor: 8.661

2.  The clinical significance of pre-operative serum CA 125 in ovarian cancer.

Authors:  D J Cruickshank; W T Fullerton; A Klopper
Journal:  Br J Obstet Gynaecol       Date:  1987-07

3.  CA 125 surveillance and second-look laparotomy in ovarian carcinoma.

Authors:  D B Atack; J A Nisker; H H Allen; E R Tustanoff; L Levin
Journal:  Am J Obstet Gynecol       Date:  1986-02       Impact factor: 8.661

4.  Elevation of CA 125 in patients with benign and malignant ascites.

Authors:  J F Bergmann; J M Bidart; M George; M Beaugrand; V G Levy; C Bohuon
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

5.  CA 125: a useful marker in endometrial carcinoma.

Authors:  J M Duk; J G Aalders; G J Fleuren; H W de Bruijn
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

6.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.

Authors:  J M Niloff; R C Bast; E M Schaetzl; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1985-04-01       Impact factor: 8.661

7.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Elevated serum concentrations of CA-125 in patients with advanced endometriosis.

Authors:  R L Barbieri; J M Niloff; R C Bast; E Scaetzl; R W Kistner; R C Knapp
Journal:  Fertil Steril       Date:  1986-05       Impact factor: 7.329

10.  Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.

Authors:  H Halila; U H Stenman; M Seppälä
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860
View more
  5 in total

1.  Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.

Authors:  E Avall-Lundqvist; K Sjövall; L O Hansson; P Eneroth
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

Review 2.  Increased CA 125 in a patient with tuberculous peritonitis: case report and review of published works.

Authors:  D K O'Riordan; A Deery; A Dorman; O E Epstein
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

3.  The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.

Authors:  R E Hawkins; K Roberts; E Wiltshaw; J Mundy; V R McCready
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

4.  Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.

Authors:  S M Scholl; C H Bascou; V Mosseri; R Olivares; H Magdelenat; T Dorval; T Palangié; P Validire; P Pouillart; E R Stanley
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

5.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.